Tianjin Pharmaceutical Da Ren Tang (SGX:T14, SHA:600329) will inject 493.6 million yuan into Tianjin Pharmaceutical Group Taiping Medicine, according to a Wednesday filing on the Singapore Exchange.
The capital injection will be carried out through the transfer of Tianjin Pharmaceutical Da Ren Tang's 100% equity interest in Tianjin Zhongxin Medicine to Tianjin Pharmaceutical Group Taiping Medicine.
This move will create a joint venture with Tianjin Pharmaceutical Holdings, which will hold a 56.7% stake in Tianjin Pharmaceutical Group Taiping Medicine.
Price (SGD): S$2.05, Change: S$+0.020, Percent Change: +0.99%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。